Monte Rosa Therapeutics and Novartis Partner on Degrader Development
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced today a new collaboration with Novartis (NYSE: NVS)...
Fovinaciclib CDK4/6 Breaks Ground in Breast‑Cancer Therapy
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196, SHA: 600196) announced that its subsidiary Avanc...
Shenzhen Kangtai Receives NMPA Approval for Sabin‑Strain Inactivated Polio Vaccine
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced today that the China National Medical...
BioRay Biopharmaceutical Secures NMPA Approval for BGM0504 in Overweight/Obesity Trials
BioRay Biopharmaceutical (SHA: 688166) announced today that its dual‑agonist drug BGM0504 has received National Medical...
Biocytogen Licenses RenMice Antibody to Tubulis, Boosting ADC Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced today that it has entered into a...
Rona Therapeutics RN3161 siRNA Targets INHBE, Submits Australian Trial Application
Shanghai‑based Rona Therapeutics Inc. announced on September 15, 2025 that it has formally submitted a Clinical Trial...
Bio-Thera Partners with Jamjoom Pharma to Launch BAT2306 Biosimilar in MENA
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced on September 15, 2025, that it has entered...
ZSCO Invests 790 m RMB in Guobang Pharma, Launches Strategic Partnership
Zhejiang State‑owned Capital Operation Co., Ltd. (ZSCO) and Guobang Pharmaceutical (SHA: 605507) announced a strategic...
CSPC Pharmaceutical Group Secures NMPA Approval for SYH2066 in RSV Trials
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its novel oral small‑molecule, SYH2066, has been...
Genrix Succeeds with Telikibart Phase 3, Targets Atopic Dermatitis
China‑based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection...
HitGen and BioAge Launch Phase I Study of BGE‑102, a Novel NLRP3 Inhibitor
China‑based HitGen Inc. (SHA: 688222) announced that its partner, BioAge Labs, Inc. (NASDAQ: BIOA), has...
Lion TCR Secures FDA Approval for LioCyx‑M004, Launching Phase Ib/II Trial in Chronic Hepatitis B
In a landmark announcement, Lion TCR disclosed that the U.S. Food and Drug Administration (FDA)...
Biokin Pharma Secures Breakthrough Therapy Designation for izalontamab with BMS
China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that its bispecific antibody‑drug conjugate...
Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal
Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant is reportedly in exploratory talks...
Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033
China‑based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with Tianjin Jikun Pharmaceutical...
BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth
A leaked internal email from US major Bristol-Myers Squibb (BMS; NYSE: BMY) has recently surfaced...
NMPA Releases 96th Reference Listed Drugs Catalog, Adding 42 New Generic Specifications
The National Medical Products Administration (NMPA) has just published the 96th edition of its Reference...
CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer
CSPC Pharmaceutical Group (HKG: 1093) announced today that Anbenitamab Antibody Injection (KN026), co‑developed with Alphamab...
BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC
BioNTech SE (NASDAQ: BNTX) and Bristol-Myers Squibb (BMS, NYSE: BMY) disclosed interim data from a...
Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference
Summit Therapeutics (NASDAQ: SMMT) disclosed longer‑term progression‑free survival (PFS) data from its HARMONi trial of...